

SANOFI-AVENTIS  
Form 6-K  
November 30, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

---

For the month of November 2007

Commission File Number: 001-31368

**SANOFI-AVENTIS**

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In November 2007, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

**Exhibit List**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated November 13, 2007: Sanofi Pasteur and Acambis join forces to bring West Nile vaccine to market.
Exhibit 99.2	Press release dated November 13, 2007: Rimonabant Regulatory Update in Europe.
Exhibit 99.3	Press release dated November 26, 2007: Sanofi-aventis to build a vaccine facility in Shenzhen for prevention of influenza and pandemic readiness in China.
Exhibit 99.4	Press release dated November 29, 2007: Sanofi-aventis initiates a major collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19%.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 29, 2007

SANOFI-AVENTIS

By /S/ P. Kodyra  
Name: Patricia Kodyra  
Title: Associate Vice President  
Financial and Securities Law

**Exhibit Index**

<u>Exhibit No.</u>	<u>Description</u>
Exhibit 99.1	Press release dated November 13, 2007: Sanofi Pasteur and Acambis join forces to bring West Nile vaccine to market.
Exhibit 99.2	Press release dated November 13, 2007: Rimonabant Regulatory Update in Europe.
Exhibit 99.3	Press release dated November 26, 2007: Sanofi-aventis to build a vaccine facility in Shenzhen for prevention of influenza and pandemic readiness in China.
Exhibit 99.4	Press release dated November 29, 2007: Sanofi-aventis initiates a major collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19%.